Excellent short-term results have been achieved by the use of percutaneous transluminal coronary angioplasty (PTCA) for the treatment of arterial narrowing (stenosis) resulting from arterial disease such as acute atherosclerosis. However, repeat PTCA is often necessary as reocclusion of the damaged area or restenosis occurs in 30-40% of cases. 1, 2 Exactly how restenosis occurs is yet to be clearly defined although aberrant smooth muscle cell proliferation has been implicated. It has been proposed that exposure of the procoagulant intimal and medial smooth muscle cell layers to the bloodstream by the removal of the endothelial cell layer during PTCA results in the initiation of the coagulation cascade and the accumulation of mitogenic products in the damaged area. These stimulate the migration and proliferation of vascular smooth muscle cells (VSMC) and the synthesis of extracellular matrix, potentially leading to re-occlusion of the injured artery. 3, 4 In accordance with the above model, recent studies aimed at preventing restenosis have focused on gene therapy approaches for the transient control of smooth muscle cell proliferation, although the total contribution of VSMC proliferation to the developing restenotic lesion is far from accepted. [5] [6] [7] Correspondence: M-C Keogh The c-myb and c-myc transcription factors play a central role in the cell cycle and have been found to be essential for VSMC replication. Both are rapidly induced following mitogenic stimulation of quiescent VSMCs in vitro and balloon catheter injury in vivo. [8] [9] [10] [11] It is now recognized that c-myc and c-myb are required to protect cells from entering the programmed cell death pathway (apoptosis) when stimulated by growth factors and blocking their expression can cause the cellular fail-safe pathways to be circumvented. [12] [13] [14] [15] Consequently, down-regulation of cmyc or c-myb provides a possible avenue for interference with VSMC proliferation associated with restenosis.
A number of gene therapy approaches for the treatment of restenosis have employed antisense strategies to inhibit VSMC proliferation. Antisense oligonucleotides targeted against c-myc and c-myb have been reported to result in reduced c-myc and c-myb protein levels and inhibition of proliferation of human and rat VSMCs in vitro. [16] [17] [18] [19] Similarly, in vivo transfection studies utilizing antisense c-myc and c-myb oligonucleotides have reported reduced c-myc or c-myb expression and reduced neointimal thickening following vascular injury in a number of animal models. 16, [20] [21] [22] However, therapeutic application of antisense oligonucleotides is hampered by cellular uptake and stability, as well as by their lack of cell-and possibly target mRNA-specificity. [23] [24] [25] [26] Consequently, antisense gene expression vectors containing the c-myc cDNA have been created and shown to reduce cmyc expression and cellular proliferation in a number of cell types. [27] [28] [29] An alternative approach to antisense strategies is to block normal protein function through the employment of competitive inhibitors or dominant negative proteins such as H-ras 30, 31 or constitutively active retinoblastoma (b) 32 mutants and indeed both have demonstrated their ability to inhibit neointimal formation in animal models. Dominant-negative c-myb expression constructs incorporating the c-myb DNA binding domain alone or coupled to the Drosophila engrailed repressor gene have allowed examination of c-myb function in T cell development. 33 Similar deletion or chimeric c-myb constructs have also been used to examine the role of c-myb in cell-cycle progression and the regulation of cytoplasmic Ca 2+ concentration in rat VSMC cell lines. 33, 34 The dominant-negative chimeric myb-engrailed (MEnT, MybEn, MERT) and myc-engrailed (MycEn) constructs used in this study were designed on the basis that the activity of c-myb and c-myc proteins is dependent on the integrity of their trans-activation and DNA-binding domains. As described previously, 33 the dominantnegative chimeric myb-engrailed gene constructs (MybEn (Figure 1a ). Deletion derivatives of myc which retain the bHLH-LZ, but not the amino-terminal transactivating domain, form biologically inactive DNA-binding dimers with Max and function as dominant negative suppressers of Myc transforming activity. 37, 38 It was postulated that the additional presence of the engrailed repressor domain would have a more pronounced effect than simple deletion mutants. 33 The two main expression plasmids utilised in this study are the pCI/h999 expression vector ( Figure 1b ) and its parent pCI (Promega), both of which have been described previously. 39 The inclusion of human VSMC ␣-actin regulatory elements in the pCI/h999 expression vector (as opposed to the CMV-containing pCI) allows the specific-targeting of VSMCs in vitro and we predict in vivo. The pCI/h999 vector has been tested in vitro in cells from a number of lineages including muscle (skeletal, cardiac and vascular smooth), endothelium (HUVEC, BAEC, PAEC), hepatocytes, fibroblasts and T cells. The vector is active in all muscle types tested, although relatively more active in VSMCs. Since the vector is intended for delivery and use in a specific anatomical location (a site of intimal hyperplasia) rather than systemically, general expression in muscle does not detract from its potential usefulness. Of the cells comprising this lesion type (VSMCs, ECs, fibroblasts, T cells and macrophages), only VSMCs will be expected to support expression. This cellular-specificity is not possible with This work describes a dominant-negative gene approach to the regulation of VSMC proliferation using chimeric myb-engrailed (MEnT, MybEn, MERT) and mycengrailed (MycEn) gene constructs ( Figure 1a) . Two of the myb-engrailed constructs utilised have been described previously: the tamoxifen-responsive, 9E10 epitopetagged MERT and the 9E10 epitope-tagged MEnT. 13, 33 An additional myb-engrailed chimera (MybEn) and a novel myc-engrailed chimera (MycEn) were created and cloned in the expression vectors pCI and pCI/h999 (Figure 1b) . 39 The sequence of the MybEn and MycEn chimeras was confirmed by DNA sequencing (data not shown). Following transfection into mammalian cells it is expected that the pCI vector will support expression of genes linked in cis in all cell types, while the genes will be expressed only in muscle cells when the pCI/h999 vector is used. 39 To confirm this expression pattern, the MycEn and MybEn constructs in the pCI or pCI/h999 vectors were transfected into rabbit VSMCs or the HUVEC cell line ECV304 as described 39, 40 and total RNA harvested 36 h later for Northern analysis. The resulting membranes were probed for engrailed or the endogenous ribosomal pro- 
. Unincorporated label was removed by PBS washing and the cells mounted in Vecta shield (Vector Laboratories, Peterborough, UK) containing DAPI for fluorescence microscopy. Microscopic determination of apoptotic and normal nuclei was determined by counting under excitation with a fluorescein filter (288 nm). Normal nuclei stain blue only, while apoptotic nuclei show co-localization of blue DAPI and green FITC. The mean percentage of apoptotic nuclei relative to normal nuclei and standard error of the mean were determined after counting cells in a minimum of eight microscopic fields. Paired Student's t tests were applied where indicated with the aid of the Sigmaplot program (SPSS UK Ltd, Surrey, UK) and significance (*) was determined as a probability that two means indicated were different at the P Ͻ 0.05 level. 4-OH-TAM, 4-hydroxytamoxifen; CPM, counts per minute; hrs, hours; VSMC, vascular smooth muscle cell.
tein S26 41 with the expected product sizes of S26, MycEn and MybEn mRNAs being 0.44, 1.43 and 1.35 kb, respectively. The expression pattern observed is as expected: transcription of MycEn and MybEn in pCI is supported in both cell types, but only in rabbit VSMCs when the pCI/h999 expression vector is used (Figure 2a ).
To demonstrate frame fidelity of each clone, the novel MybEn and MycEn chimeras in the pCI and pCI/h999 expression vectors were subjected to in vitro transcription/translation. The enzymatic activity of the luciferase gene transcribed/translated from pCI Luc or pCI/h999 Luc was used as a positive control for the method (data not shown). The translation products observed are shown (Figure 2b ) and their respective sizes correspond to the production of the appropriate fulllength proteins.
The construction of the myb-engrailed-tamoxifen responsive chimera (MERT) has been described previously. 13, 33 A stably transfected rat VSMC MERT + line was created for initial studies of the effect of mybengrailed chimeric proteins on a relatively homogeneous population. The addition of 4-hydroxytamoxifen (4-OH-TAM) to these stable integrants is assumed to cause translocation of the MERT + protein from the cytoplasm to the nucleus of expressing cells to exert its effects. 42 Stable MERT + rat VSMC and untransfected rat VSMC were cultured in the presence of 0-100 nm 4-OH-TAM for 0-72 h. Analysis of cell proliferation by incorporation of tritiated thymidine revealed that the MERT + cells showed dosedependent 4-OH-TAM inhibition of cell proliferation within 48 h of addition. After 4 days culture in the presence of 100 nm 4-OH-TAM the rate of thymidine incorporation of the MERT + transfectants was only 30% of that observed for MERT + cells grown in the absence of 4-OH-TAM. In contrast, proliferation of untransfected rat smooth muscle cells was unaffected by 4-OH-TAM addition (Figure 3a) .
The TUNEL procedure was used to determine whether the inhibition of proliferation observed in rat VSMC MERT + transfectants treated with 4-OH TAM was a consequence of apoptosis. Apoptotic nuclei could be observed as soon as 4 h after the addition of 100 nm 4-OH-TAM to the MERT + population and their proportion relative to normal nuclei increased steadily (and significantly at each time-point (P Ͻ 0.05)) to represent 20% of the population by 16 h (Figure 3b ). In contrast, little change in the level of apoptosis was evident over the 16 h when untransfected cells were grown in the presence of 100 nm 4-OH-TAM.
Although stable integrants such as the MERT + rat VSMC line are useful for functional studies, a gene therapy protocol for a transient condition such as intimal hyperplasia might more rationally exploit transient transfection. Thus the activity of the novel myb-and mycengrailed chimeras we assembled were examined in vitro under these conditions. Primary human VSMCs were transiently transfected with pCI, the chimeric proteins MybEn or MycEN in pCI or pCINeo MEnT as indicated. The proliferation of each population was determined by tritiated thymidine incorporation after 48 h and the level of apoptosis by TUNEL at 24 h. A reduction in the proliferation level is seen with MybEn-, MycEn-and MEnT-transfected populations versus pCI-transfected (Figure 4a ). This reduction in proliferation is accompanied by the induction of apoptosis (Figure 4b ). The induction of apoptosis by myb-engrailed chimeras was not unexpected as previous studies have shown them to mediate apoptosis by a pathway which can be inhibited by bcl-2 in T cells. 13 It should be understood, however, that lymphocytes are widely acknowledged to be on a 'hair-trigger' to apoptosis and thus fin- Figure 3a) dings in these cells may not translate well to other tissues. Other studies utilizing c-myb cDNA lacking the DNAbinding domain as well as a myb-engrailed fusion demonstrated that in addition to its effect on the cell cycle, cmyb has a role in regulating intracellular stores of calcium. 34 For c-myc to induce apoptosis, however, it requires association with its dimerisation partner Max. 43 In addition, Myc-induced apoptosis is usually associated with c-myc overexpression, 44 although the reverse appears to hold for some B-lymphocyte lines. 45 It is possible that apoptosis induced by chimeric MycEn is due to its overexpression and dimerisation with Max, rather than by directly interfering with endogenous c-myc function.
cells per well in sextuplet) were transiently transfected with empty vector pCI, the chimeric proteins MybEn or MycEN in pCI, or pCINeo MEnT as indicated (transfection efficiency determined as approximately 40%). The proliferation of each population was assayed by a 4-h tritiated thymidine pulse (as per
To increase the usefulness of these constructs further for the treatment of a condition such as intimal hyperplasia, the ability to target VSMCs specifically is desirable. For this reason the chimeric genes were cloned into the pCI/h999 expression vector which specifically supports transcription in muscle lineages only (Figure 2a) . 39 Primary rat and rabbit VSMCs, the HUVEC cell line ECV304 or bovine aortic endothelial cells (BAECs) were then transiently transfected with pCI, pCINeo MEnT, or the chimeric proteins MybEn or MycEN in pCI or pCI/h999 as indicated. The proliferation of each population was determined by tritiated thymidine incorporation after 48 h and the level of apoptosis by TUNEL at 24 h. Transfection of the luciferase reporter gene in pCI or pCI/h999 was performed to demonstrate efficient transfection of the lineages and the specificity of the pCI/h999 vector in each case (Figure 5a) .
Coupling of the human VSMC ␣-actin transcriptional enhancer in cis to MybEn and MycEn confers VSMC-specific cytopathicity. A reduction in the proliferation level is seen with both MybEn and MycEn in all populations transfected with the pCI form, but only in VSMCs if the pCI/h999 vector is used (Figure 5b ). This specific reduction in proliferation is accompanied by the specific induction of apoptosis (Figure 5c ). A significant increase in the apoptosis level is observed for all constructs (pCI or pCI/h999 forms) relative to the empty vector pCI (P Ͻ 0.05) in the rabbit VSMC populations while BAECs are only affected when transfected with constitutively expressed cassettes (pCI form only). This reflects the fact that transcription is unsupported by the pCI/h999 vector in non-VSMCs (Figures 2a and 5a) .
In summary, our findings demonstrate that expression of the chimeric dominant-negative myb-and mycengrailed proteins described can dramatically decrease the proliferation level of an exponentially growing population, due at least in part to the induction of apoptosis. Experiments have shown that even in the case of VSMCs which stably express the inducible myb-engrailed protein MERT, only a percentage of the population is targeted for apoptosis following induction. Furthermore, by the coupling of these constructs to the human VSMC ␣-actin smooth muscle promoter/enhancer we were able to demonstrate VSMC-specific expression and action of the dominant-negative constructs. Together, these findings have a potential application in gene therapy-mediated regulation of VSMC proliferation/extracellular matrix production in the developing restenotic lesion.
The advantages of the constructs we describe here over those previously utilized are many-fold: the inclusion of the VSMC ␣-actin regulatory elements in the pCI/h999 expression vectors allows the specific targeting of VSMCs in vitro and we predict in vivo. The use of the dominantnegative approach also contributes to specific cell targeting, as opposed to the by stander effect observed with gene-prodrug therapies such as the HSVtk gene and gancyclovir. Another advantage of the myb-and mycengrailed chimeras is their apparent inability to block cell proliferation completely, even in a stably transformed VSMC population. In the treatment of restenosis, this is a desirable outcome as the aim is to reduce the proliferation of the VSMC pool, not destroy it completely. With the advent of more efficient methods of gene delivery, such that a greater percentage of cells in the vessel wall could be transfected, it could be important to utilize an inducible system. The studies we describe show mybengrailed chimeras to be amenable to the tamoxifeninducible system, while previous studies have shown the activity of a c-myc-ER fusion. 46 Finally, the chimeric c-myb and c-myc constructs were found to be very effective at inhibiting VSMC proliferation in rat, rabbit and human VSMCs by a mechanism which involves apoptosis. A percentage of VSMCs undergo apoptosis in the vascular remodeling which occurs during the development of restenosis. [47] [48] [49] Thus the controlled induction of apoptosis in the remodeling vessel attempts to improve on the endogenous situation.
